Cargando…

Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study

BACKGROUND: Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Lai, Xingqiang, Guo, Yuhe, Ma, Junjie, Fang, Jiali, Li, Guanghui, Xu, Lu, Yin, Wei, Chen, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425735/
https://www.ncbi.nlm.nih.gov/pubmed/34493167
http://dx.doi.org/10.1080/0886022X.2021.1968432
_version_ 1783749897290252288
author Zhang, Lei
Lai, Xingqiang
Guo, Yuhe
Ma, Junjie
Fang, Jiali
Li, Guanghui
Xu, Lu
Yin, Wei
Chen, Zheng
author_facet Zhang, Lei
Lai, Xingqiang
Guo, Yuhe
Ma, Junjie
Fang, Jiali
Li, Guanghui
Xu, Lu
Yin, Wei
Chen, Zheng
author_sort Zhang, Lei
collection PubMed
description BACKGROUND: Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. METHODS: From March 2011 to January 2013, 11 renal transplanted patients with IFTA were recruited. At baseline, patients were given one intra-arterial infusion of BM-MSCs; 7 days and 1 month later, another two intravenous infusions of cells were followed. Serum creatinine, creatinine clearance rate, and serum cystatin-C at baseline and 7 days, 1 month, 3 months, 6 months, and 12 months after the intra-arterial infusion of BM-MSCs were used to assess renal function. At baseline and 6 months, histological examination based on hematoxylin-eosin, Masson’s trichrome and periodic acid-Schiff staining and immunohistochemistry for transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF) was performed. Adverse events were recorded to evaluate the safety of BM-MSCs treatment. RESULTS: At 12 months, the renal function of 6 patients (54.5%) was improved, 3 (27.3%) were stable and 2 (18.2%) were worsened. At 6 months, the mean IFTA scores of all participators were similar with the baseline (1.73 ± 0.41 vs.1.50 ± 0.0.77, p = 0.242); however, it was significantly decreased when only 6 patients with improved renal function were analyzed (1.67 ± 0.41 vs. 1.08 ± 0.20, p = 0.013). Besides, decreased expression of TGF-β1 and CTGF were also observed at 6 months. During 1 year follow-up period, only two minor complications including infection and allergy were observed. CONCLUSION: Our results demonstrated that autologous BM-MSCs are safe and beneficial for IFTA patients. Abbreviations: MSCs: mesenchymal stem cells; BM-MSCs: marrow-derived mesenchymal stem cells; IFTA: interstitial fibrosis and tubular atrophy; CAN: chronic allograft nephropathy; CNIs: calcineurin inhibitors; Scr: serum creatinine; CCr: creatinine clearance rate; Cys-C: cystatin-C; TGF-β1: transforming growth factor β1; CTGF: connective tissue growth factor
format Online
Article
Text
id pubmed-8425735
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84257352021-09-09 Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study Zhang, Lei Lai, Xingqiang Guo, Yuhe Ma, Junjie Fang, Jiali Li, Guanghui Xu, Lu Yin, Wei Chen, Zheng Ren Fail Clinical Study BACKGROUND: Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated. METHODS: From March 2011 to January 2013, 11 renal transplanted patients with IFTA were recruited. At baseline, patients were given one intra-arterial infusion of BM-MSCs; 7 days and 1 month later, another two intravenous infusions of cells were followed. Serum creatinine, creatinine clearance rate, and serum cystatin-C at baseline and 7 days, 1 month, 3 months, 6 months, and 12 months after the intra-arterial infusion of BM-MSCs were used to assess renal function. At baseline and 6 months, histological examination based on hematoxylin-eosin, Masson’s trichrome and periodic acid-Schiff staining and immunohistochemistry for transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF) was performed. Adverse events were recorded to evaluate the safety of BM-MSCs treatment. RESULTS: At 12 months, the renal function of 6 patients (54.5%) was improved, 3 (27.3%) were stable and 2 (18.2%) were worsened. At 6 months, the mean IFTA scores of all participators were similar with the baseline (1.73 ± 0.41 vs.1.50 ± 0.0.77, p = 0.242); however, it was significantly decreased when only 6 patients with improved renal function were analyzed (1.67 ± 0.41 vs. 1.08 ± 0.20, p = 0.013). Besides, decreased expression of TGF-β1 and CTGF were also observed at 6 months. During 1 year follow-up period, only two minor complications including infection and allergy were observed. CONCLUSION: Our results demonstrated that autologous BM-MSCs are safe and beneficial for IFTA patients. Abbreviations: MSCs: mesenchymal stem cells; BM-MSCs: marrow-derived mesenchymal stem cells; IFTA: interstitial fibrosis and tubular atrophy; CAN: chronic allograft nephropathy; CNIs: calcineurin inhibitors; Scr: serum creatinine; CCr: creatinine clearance rate; Cys-C: cystatin-C; TGF-β1: transforming growth factor β1; CTGF: connective tissue growth factor Taylor & Francis 2021-09-07 /pmc/articles/PMC8425735/ /pubmed/34493167 http://dx.doi.org/10.1080/0886022X.2021.1968432 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Zhang, Lei
Lai, Xingqiang
Guo, Yuhe
Ma, Junjie
Fang, Jiali
Li, Guanghui
Xu, Lu
Yin, Wei
Chen, Zheng
Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title_full Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title_fullStr Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title_full_unstemmed Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title_short Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
title_sort autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: a pilot study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425735/
https://www.ncbi.nlm.nih.gov/pubmed/34493167
http://dx.doi.org/10.1080/0886022X.2021.1968432
work_keys_str_mv AT zhanglei autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT laixingqiang autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT guoyuhe autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT majunjie autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT fangjiali autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT liguanghui autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT xulu autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT yinwei autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy
AT chenzheng autologousbonemarrowderivedmesenchymalstemcellsforinterstitialfibrosisandtubularatrophyapilotstudy